This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

New research has found that nearly 137 million adults—or more than half of all U.S. adults—are eligible for semaglutide ...

Learn about typical dosages of atorvastatin oral tablet for high cholesterol and heart-related risks, including what’s ...

NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...

NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...